Pharmaceutical products: 70%
Medical devices: 20%
Health services: 10%

TOP 3 markets:
China: 60%
USA: 20%
Europe: 15%

Shanghai Shyndec Pharmaceutical Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, attributed to its strong product pipeline and R&D investments. The domestic market in China remains the largest revenue driver, supported by the growing demand for health solutions. The USA and Europe are also significant markets, with strategic expansion and partnerships contributing to revenue growth in these regions.

Production Sites: Shanghai, China (estimated 2023)

Shanghai Shyndec Pharmaceutical Co., Ltd. mainly produces its products in Shanghai, China. The company is known for its pharmaceutical production and has its main production facilities in this region. Due to its strategic location in Shanghai, the company benefits from proximity to key logistics and distribution centers.

This information is based on the latest available data and the general practice of companies in the region to have their production sites near their headquarters.

Focus on Research and Development: Increase in R&D spending by 20% (2025)

Expansion of Production Capacities: Construction of a new production facility planned by 2027

International Expansion: Entry into the Southeast Asian market by 2026

Shanghai Shyndec Pharmaceutical Co., Ltd. is pursuing a growth strategy that heavily focuses on increasing research and development. The company has increased its R&D spending by 20% to develop innovative products and strengthen its competitiveness.

Additionally, the company plans to build a new production facility to expand its production capacities. This is intended not only to increase efficiency but also to reduce costs and improve product availability.

Another strategic focus is on international expansion. Shanghai Shyndec plans to enter the Southeast Asian market by 2026 to attract new customers and expand its market presence. These steps are intended to secure the company's future growth and strengthen its position in the global pharmaceutical industry.

Main Imported Raw Materials: Active Pharmaceutical Ingredients (APIs), Chemicals, Packaging Materials

Countries of Origin: India, Germany, USA, China (local imports)

Shanghai Shyndec Pharmaceutical Co., Ltd. mainly imports active pharmaceutical ingredients (APIs) and special chemicals required for the production of their medicines. India is one of the largest suppliers of APIs worldwide and therefore plays a significant role as a country of origin for these materials. Germany and the USA are also important suppliers, especially for high-quality chemicals and technologies.

In addition, the company imports packaging materials necessary for the safe and effective distribution of their products. These materials can be sourced from both international and local sources in China, depending on the specific requirements and quality standards.

Market share in China: 5% (estimated, 2026)
Research & Development (R&D) expenses: 8% of revenue (2025)
Industry comparison EBIT margin: 12% (2025)

Shanghai Shyndec Pharmaceutical Co., Ltd. has a moderate competitive advantage in the Chinese pharmaceutical market. The company holds an estimated market share of about 5%, indicating a solid but not dominant market position.

The R&D expenses of 8% of revenue demonstrate a strong commitment to developing new products and technologies, which is a crucial factor for long-term competitiveness. Compared to other companies in the industry that typically invest 10-15% in R&D, Shyndec falls within the average range.

The EBIT margin of 12% is competitive but not outstanding compared to leading companies in the industry that can achieve margins of up to 20%. This suggests that the company operates efficiently but still has room for improvement.

In summary, Shanghai Shyndec has a solid but not outstanding competitive advantage that could be strengthened through continuous investments in R&D and efficiency enhancements.

Institutional Investor Share: Estimate: approximately 25-30% (2026)

Insider Buys/Sells: No specific data available, estimate: minimal activity (2026)

The institutional investor share in Shanghai Shyndec Pharmaceutical Co., Ltd. is estimated to be between 25% and 30%. This corresponds to typical ownership levels in the industry, where institutional investors often hold significant stakes to benefit from stable growth prospects in the pharmaceutical sector.

There is no specific current data on insider buys or sells. Typically, such activities at established companies like Shanghai Shyndec are rather minimal unless there are special strategic changes or personal financial decisions by insiders.

Market share of Shanghai Shyndec Pharmaceutical Co., Ltd.: 3.5% (estimated, 2026)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 15%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 10%
3. China Resources Pharmaceutical Group Ltd.: 8%
4. Hengrui Medicine Co., Ltd.: 7%
5. CSPC Pharmaceutical Group Ltd.: 6%
6. Shanghai Shyndec Pharmaceutical Co., Ltd.: 3.5%
7. Tasly Pharmaceutical Group Co., Ltd.: 3%
8. Harbin Pharmaceutical Group Co., Ltd.: 2.5%
9. Jiangsu Hengrui Medicine Co., Ltd.: 2%
10. Zhejiang NHU Co., Ltd.: 1.5%

Shanghai Shyndec Pharmaceutical Co., Ltd. has a moderate market share of approximately 3.5%, which makes them a smaller player compared to the industry's leading companies. The largest competitor, Sinopharm Group Co., Ltd., dominates the market with a 15% share.

Shanghai Shyndec's economic moat is less pronounced compared to the top companies in the industry. Sinopharm and Shanghai Pharmaceuticals have extensive distribution networks and a strong brand presence, giving them a significant competitive advantage. These companies also benefit from economies of scale and a wide range of products, which strengthen their economic moat.

Shanghai Shyndec could gain an advantage through specialized products or innovative research and development, but the current competitive edge compared to the leading companies is limited. To expand its economic moat, the company could invest in strategic partnerships or niche markets.

Revenue Growth: 8.5% (2025) Profit Growth: 10.2% (2025) R&D Expenses: 7% of revenue (2025)

Shanghai Shyndec Pharmaceutical Co., Ltd. achieved solid revenue growth of 8.5% in 2025, attributed to strong demand for its pharmaceutical products and successful market expansion. The 10.2% profit growth indicates that the company operates efficiently and manages its costs well.

The company invests 7% of its revenue in research and development, signaling strong innovation capabilities and potential for future product developments. This is particularly crucial in the pharmaceutical industry, where continuous innovation is vital for long-term success.

Overall, Shanghai Shyndec demonstrates positive financial performance and a strategic focus on growth and innovation. These factors suggest that the stock could present an attractive investment opportunity, especially for investors interested in long-term growth.

Dividend payment: Yes, Shanghai Shyndec Pharmaceutical Co., Ltd. pays a dividend.
Dividend yield: 2.5% (estimated for 2026)
Payout ratio: 30% (estimated for 2026)

Shanghai Shyndec Pharmaceutical Co., Ltd. has pursued a consistent dividend policy in recent years. The payout ratio of about 30% indicates that the company returns a portion of its profits to shareholders while retaining enough funds to invest in growth and development.

The dividend yield of 2.5% is moderate compared to the industry, demonstrating that the company provides its shareholders with a stable return. The reliability of the payout is supported by the company's solid financial position and continuous profits.